Dr. Rongze Yang received his medical degree in Internal Medicine and Ph.D. in Molecular Medicine from Sun Yat-sen University in China in 1994. He did his postdoctoral fellow training in molecular genetics and cell biology at University of Maryland School of Medicine in Baltimore and then joined the faculty as a research assistant professor in Department of Medicine. In 2017, he was recruited to Vigene Biosciences, a CDMO for manufacturing plasmid DNA and different viral vectors including AAV for research and clinical use. He initially served as Director of Plasmid Production, later as Director of Upstream Process Development & cGMP Manufacturing of Viral Vectors. After Vigene was acquired by Charles River Laboratories. Inc in 2021, he was promoted to Senior Director of Process Development to lead both upstream and downstream process development for vial vector production. In 2022, he joined AAVnerGene as director of vector engineering and viral vector production to develop new technologies for improving the efficacy of AAV manufacturing.
